EXEL (Exelixis) Cash Flow for Lease Financing : $0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cash Flow for Lease Financing?

Exelixis's Cash Flow for Lease Financing for the three months ended in Mar. 2025 was $0 Mil. Exelixis's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 was $0 Mil.

Compared with last quarter ($0 Mil in Dec. 2024 ), Exelixis's Cash Flow for Lease Financing remained the same in Mar. 2025 ($0 Mil).

Exelixis Cash Flow for Lease Financing Historical Data

The historical data trend for Exelixis's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cash Flow for Lease Financing Chart

Exelixis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow for Lease Financing

Get a 7-Day Free Trial

Exelixis Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow for Lease Financing	Get a 7-Day Free Trial															-	-	-	-	-

Exelixis Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Exelixis Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Exelixis's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

1EXEL:Italy 0IJO:UK EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Julie Smith	director	C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Maria C Freire	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022